The data presented in Figure 3 indicate that SGLT2 inhibitors lower the likelihood of worsening heart failure or cardiovascular death by 21% when compared to the control group (HR = 0.79; 95% CI: 0.69 to 0.89). This evidence concerns the gene SLC5A2 and heart failure.